Shandong Buchang Pharmaceutical Co., Ltd. announced that some of its subsidiaries’ drugs will be selected in the continued procurement of varieties after the expiration of the national organization’s collective drug purchase agreement.
Securities code: 603858 Securities abbreviation: Buchang Pharmaceutical Announcement number: 2026-022
Shandong Buchang Pharmaceutical Co., Ltd.
Announcement on the plans for some of the subsidiaries’ drugs to be selected in the continued procurement of varieties upon expiration of the national organization’s collective drug purchase agreement.
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Recently, Shaanxi Buchang High-tech Pharmaceutical Co., Ltd., Shaanxi Buchang Pharmaceutical Co., Ltd., Shandong Danhong Pharmaceutical Co., Ltd., and its holding subsidiary Jilin Tiancheng Pharmaceutical Co., Ltd., the wholly-owned subsidiaries of Shandong Buchang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), participated in the continued procurement of varieties after the expiration of the collective drug agreement (hereinafter referred to as the "continuation procurement") organized by the national organization's centralized procurement drug agreement expiration variety procurement office (hereinafter referred to as the "continuation procurement office"). According to the "Announcement of the Result of Proposed Continuation Procurement of Varieties upon Expiration of the National Organized Concentrated Drug Purchase Agreement" issued by the Continuation Procurement Office on February 10, 2026, some of the subsidiaries' drugs are planned to be selected for this continuation procurement. The relevant information is now announced as follows:
1. Basic information about the drug to be selected
Proposed company to be selected Drug name Indications Specifications Ammonium besylate is used for hypertension, chronic stable angina pectoris, vasospastic angina pectoris 5mg Dipine tablets and coronary heart disease confirmed by angiography.
- Adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE) 2. Treatment of deep vein thrombosis (DVT) in adults
and pulmonary embolism (PE); DVT after completion of at least 6 months of initial treatment
Shaanxi Bu Changgao
For the reduction of DVT in patients with persistent risk of recurrent PE and/or
Rivaroxaban Tablets 10mg New Pharmaceutical Co., Ltd.
and/or risk of recurrence of PE. 3. Having one or more risk factors (e.g.
Such as: congestive heart failure, hypertension, age ≥75 years, diabetes, company
To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (with a history of stroke or transient ischemic attack).
For the treatment of hypertension, angina pectoris, myocardial infarction, hypertrophic cardiomyopathy, 25mg Metoprolol Tartrate
Aortic dissection, arrhythmia, hyperthyroidism, cardioneurol tablets
50mg
Neurosis, etc. In recent years, it has been used for the treatment of heart failure.
Lacosamide tablets manufactured by Shaanxi Buchang are used for monotherapy and combined treatment of partial seizures in patients with epilepsy aged 4 years and above. 50mg is proposed to be the selected company. Drug name Indications Specifications Pharmaceutical Co., Ltd. 100mg Pregabalin Gum made by Shandong Danhong
For the treatment of post-herpetic neuralgia and fibromyalgia. 75mg Pharmaceutical Co., Ltd. Capsules
Torsemide injection made by Jilin Tiancheng is suitable for patients with congestive heart failure who need rapid diuresis or who cannot take oral diuresis 2ml: 10 Pharmaceutical Co., Ltd. ejaculation exhaustion, liver cirrhosis, ascites, and edema caused by kidney disease. mg Note 1: According to the procurement rules of this time, the company is temporarily unable to calculate the planned supply quantity;
Note 2: The procurement cycle of the drugs to be selected this time is from the actual implementation date of the winning results to December 31, 2028.
2. The impact of this proposed election on the company
The sales revenue of the products to be selected in 2024 and the first three quarters of 2025:
Annual sales in 2024 account for the company's 2024 first three quarters of 2025 account for the company's preface to 2025
Drug Name Sales Revenue (Single Year Operating Income Degree Sales Revenue Third Quarter Operating Income No.
(digit: 10,000 yuan) Proportion (%) (Unit: 10,000 yuan) Proportion (%) 1 Amlodipine besylate tablets 944.61 0.0858 852.30 0.1006 2 Rivaroxaban tablets 12.41 0.0011 12.88 0.0015 3 Metoprolol tartrate tablets 2,387.86 0.2170 907.04 0.1071 4 Lacosamide tablets 442.90 0.0402 555.30 0.0656 5 Pregabalin capsules - - 132.52 0.0156 6 Torsemide injection 435.37 0.0396 421.27 0.0497 Note: Among the above income, the income in the first three quarters of 2025 has not been audited.
During this continued procurement cycle, medical institutions will give priority to the selected drugs in this centralized drug procurement and ensure that the agreed purchase volume is completed. If the proposed product is confirmed to be selected, a purchase and sales contract is signed and implemented, it will help the company further expand the sales of related products, increase market share, enhance the company's brand influence, and have a positive impact on the company's future operating performance.
3. Risk warning
Subsequent matters such as the signing of purchase contracts for the above products are still uncertain. The company will pay close attention to this matter
As for the progress of the project and timely performance of information disclosure obligations, investors are advised to make prudent decisions and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Shandong Buchang Pharmaceutical Co., Ltd.
February 12, 2026